H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx (CDNA – Research Report) today. The company’s shares closed yesterday at $11.87.
According to TipRanks, Chen is an analyst with an average return of -12.2% and a 30.88% success rate. Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Vaccitech Plc, and Veru.
CareDx has an analyst consensus of Strong Buy, with a price target consensus of $31.50.
See the top stocks recommended by analysts >>
Based on CareDx’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $79.36 million and a GAAP net loss of $16.94 million. In comparison, last year the company earned a revenue of $75.59 million and had a GAAP net loss of $11.9 million
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDNA in relation to earlier this year. Most recently, in November 2022, George Bickerstaff, a Director at CDNA bought 15,000.00 shares for a total of $18,300.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Read More on CDNA: